Burosumab for X-linked Hypophosphataemia and Tumour-induced Osteomalacia in Adults.
AI interpretation is pending for this paper.
Open original publication →What the AI sees
Not AI summarized yet.
Research significance
Pending deeper interpretation.
Source abstract
X-linked hypophosphataemia and tumour-induced osteomalacia are rare, distinct metabolic conditions that can affect both children and adults, and result in elevated fibroblast growth factor-23 levels and subsequent low phosphate levels. This leads to severe musculoskeletal symptoms and complications, and these conditions carry significant disease burden and high levels of morbidity. In this article, we examine the conditions and analyse the use of burosumab, a recently developed monoclonal antibody treatment, in the care of adults with these conditions.